Deal includes warrant coverage; proceeds fund Europe launch of Mysimba
By Devika Patel
Knoxville, Tenn., Sept. 10 – Orexigen Therapeutics, Inc. raised $60 million private placement of stock with funds managed by the Baupost Group, LLC on Sept. 10, according to an 8-K filed Thursday with the Securities and Exchange Commission.
The company sold 20 million common shares at $3.00 per share, which is a 14.5% premium to the Sept. 9 closing share price of $2.62.
The investors also received five-year warrants for 5 million shares. Each warrant is exercisable at $6.00. The strike price is a 129.01% premium to the Sept. 9 closing price.
Proceeds will be used to initiate a launch of Mysimba in Europe, for acquisitions and general working capital purposes.
San Diego-based Orexigen is a biopharmaceutical company focused on development of treatments of obesity.
| Issuer: | Orexigen Therapeutics, Inc.
|
| Issue: | Common shares
|
| Amount: | $60 million
|
| Shares: | 20 million
|
| Price: | $3.00
|
| Warrants: | For 5 million shares
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $6.00
|
| Investor: | Baupost Group, LLC
|
| Settlement date: | Sept. 10
|
| Stock symbol: | Nasdaq: OREX
|
| Stock price: | $2.62 at close Sept. 9
|
| Market capitalization: | $366.15 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
